Citations Appearing in 2014

  1. Baek, I.-H., B.-Y. Lee, J.-W. Chae, G.Y. Song, W. Kang and K.-I. Kwon. Development of a pharmacokinetic/pharmacodynamic/disease progression model in NC/Nga mice for development of novel anti-atopic dermatitis drugs. Xenobiotica 44(11): 1-13, 2014.
  2. Boak, L.M., C.R. Rayner, M.L. Grayson, D.L. Paterson, D. Spelman, S. Khumra, . . .and J.B. Bulitta. Clinical Population Pharmacokinetics and Toxicodynamics of Linezolid. Antimicrobial Agents and Chemotherapy 58(4): 2334-2343, 2014.
  3. Boisson, M., M. Jacobs, N. Grégoire, P. Gobin, S. Marchand, W. Couet and O. Mimoz. Comparison of Intrapulmonary and Systemic Pharmacokinetics of Colistin Methanesulfonate (CMS) and Colistin after Aerosol Delivery and Intravenous Administration of CMS in Critically Ill Patients. Antimicrobial Agents and Chemotherapy 58(12): 7331-7339, 2014.
  4. Cao, Y. and W. Jusko. Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies. Journal of Pharmacokinetics and Pharmacodynamics 41(4): 375-387, 2014.
  5. Cao, Y. and W. Jusko. Survey of monoclonal antibody disposition in man utilizing a minimal physiologically-based pharmacokinetic model. Journal of Pharmacokinetics and Pharmacodynamics 41(6): 571-580, 2014.
  6. Cardone, K.E., W.Z. Chen, D.W. Grabe, A. Batzold, H.J. Manley and T.P. Lodise. Evaluation of the pharmacodynamic profile of commonly used intravenous vancomycin dosing schemes in patients on automated peritoneal dialysis. Journal of Antimicrobial Chemotherapy 69(7): 1873-1876, 2014.
  7. Cardone, K.E., D.W. Grabe, E.J. Zasowski and T.P. Lodise. Reevaluation of Ceftazidime Dosing Recommendations in Patients on Continuous Ambulatory Peritoneal Dialysis. Antimicrobial Agents and Chemotherapy 58(1): 19-26, 2014.
  8. Catherine M. T. Sherwin, P.N., Senthilkumar Sadhasivam and Alexander A. Vinks. Utilization of Optimal Study Design for Maternal and Fetal Sheep Propofol Pharmacokinetics Study: A Preliminary Study Curr Clin Pharmacol 9(1): 64-69, 2014.
  9. Cobelli, C., C. Dalla Man, M.G. Pedersen, A. Bertoldo and G. Toffolo. Advancing Our Understanding of the Glucose System via Modeling: A Perspective. Ieee Transactions on Biomedical Engineering 61(5): 1577-1592, 2014.
  10. Davda, J.P., M.G. Dodds, M.A. Gibbs, W. Wisdom and J.P. Gibbs. A model-based meta-analysis of monoclonal antibody pharmacokinetics to guide optimal first-in-human study design. Mabs 6(4): 1094-1102, 2014.
  11. Dong, M., T. Fukuda and A.A. Vinks. Optimization of Mycophenolic Acid Therapy Using Clinical Pharmacometrics. Drug Metabolism and Pharmacokinetics 29(1): 4-11, 2014.
  12. Drusano, G., W. Liu, S. Fikes, R. Cirz, N. Robbins, S. Kurhanewicz, . . .and A. Louie. Interaction of Drug- and Granulocyte-Mediated Killing of Pseudomonas aeruginosa in a Murine Pneumonia Model. Journal of Infectious Diseases 210(8): 1319-1324, 2014.
  13. Drusano, G.L., M. Neely, M. Van Guilder, A. Schumitzky, D. Brown, S. Fikes, . . .and A. Louie. Analysis of Combination Drug Therapy to Develop Regimens with Shortened Duration of Treatment for Tuberculosis. PLoS ONE 9(7): e101311, 2014.
  14. Felton, T.W., W.W. Hope and J.A. Roberts. How severe is antibiotic pharmacokinetic variability in critically ill patients and what can be done about it? Diagnostic Microbiology and Infectious Disease 79(4): 441-447, 2014.
  15. Felton, T.W., K. McCalman, I. Malagon, B. Isalska, S. Whalley, J. Goodwin, . . .and W.W. Hope. Pulmonary Penetration of Piperacillin and Tazobactam in Critically Ill Patients. Clinical Pharmacology & Therapeutics 96(4): 438-448, 2014.
  16. Felton, T.W., J.A. Roberts, T.P. Lodise, M. Van Guilder, E. Boselli, M.N. Neely and W.W. Hope. Individualization of Dosing of Piperacillin for Critically Ill Patients: Dosing Software to Optimize Antimicrobial Therapy. Antimicrobial Agents and Chemotherapy 58(7): 4094-4102, 2014.
  17. Fischer, J.H., G.E. Sarto, J. Hardman, L. Endres, T.M. Jenkins, S.J. Kilpatrick, . . .and K.A. Rodvold. Influence of Gestational Age and Body Weight on the Pharmacokinetics of Labetalol in Pregnancy. Clinical Pharmacokinetics 53(4): 373-383, 2014.
  18. Ganic, E., S. Gundry, Z. Jianmin and M.U. Uyar (2014). Evaluation of anti-cancer therapy using in silico analysis of treatments for HER2+ breast cancer. Medical Measurements and Applications (MeMeA), 2014 IEEE International Symposium on.
  19. Gérard, C., J. Stocco, A. Hulin, B. Blanchet, C. Verstuyft, F. Durand, . . .and M. Tod. Determination of the Most Influential Sources of Variability in Tacrolimus Trough Blood Concentrations in Adult Liver Transplant Recipients: A Bottom-Up Approach. The AAPS Journal 16(13): 1-13, 2014.
  20. Gergs, U., T. Clauss, D. Ihlefeld, M. Weiss, K. Pönicke, G.O. Hofmann and J. Neumann. Pharmacokinetics of ceftriaxone in plasma and bone of patients undergoing hip or knee surgery. Journal of Pharmacy and Pharmacology 66(11): 1552-1558, 2014.
  21. Gontijo, A.V.L., J. Brillault, N. Grégoire, I. Lamarche, P. Gobin, W. Couet and S. Marchand. Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats. 1. Ciprofloxacin, Moxifloxacin and Grepafloxacin. Antimicrobial Agents and Chemotherapy 58(7): 3942-3949, 2014.
  22. Hao, K., Y. Chen, X. Zhao and X. Liu. Pharmacokinetic-pharmacodynamic model of the antihypertensive interaction between telmisartan and hydrochlorothiazide in spontaneously hypertensive rats. Journal of Pharmacy and Pharmacology 66(8): 1112-1121, 2014.
  23. Harrold, J. and A. Abraham. Ubiquity: a framework for physiological/mechanism-based pharmacokinetic/pharmacodynamic model development and deployment. Journal of Pharmacokinetics and Pharmacodynamics 41(2): 141-151, 2014.
  24. Heine, H.S., A. Louie, J.J. Adamovicz, K. Amemiya, R.L. Fast, L. Miller, . . .and G.L. Drusano. Evaluation of Imipenem for Prophylaxis and Therapy of Yersinia pestis Delivered by Aerosol in a Mouse Model of Pneumonic Plague. Antimicrobial Agents and Chemotherapy 58(6): 3276-3284, 2014.
  25. Höcht, C., F.M. Bertera, J.S. Del Mauro and C.A. Taira. Models for evaluating the pharmacokinetics and pharmacodynamics for β-blockers. Expert Opinion on Drug Metabolism & Toxicology 10(4): 525-541, 2014.
  26. Jacus, M.O., S.L. Throm, D.C. Turner, Y.T. Patel, B.B. Freeman Iii, M. Morfouace, . . .and C.F. Stewart. Deriving therapies for children with primary CNS tumors using pharmacokinetic modeling and simulation of cerebral microdialysis data. European Journal of Pharmaceutical Sciences 57(0): 41-47, 2014.
  27. Jelliffe, R.W., M. Milman, A. Schumitzky, D. Bayard and M. Van Guilder. A Two-Compartment Population Pharmacokinetic-Pharmacodynamic Model of Digoxin in Adults, With Implications for Dosage. Therapeutic Drug Monitoring 36(3): 387-393, 2014.
  28. Koch, G., W. Krzyzanski, J. Pérez-Ruixo and J. Schropp. Modeling of delays in PKPD: classical approaches and a tutorial for delay differential equations. Journal of Pharmacokinetics and Pharmacodynamics 41(4): 291-318, 2014.
  29. Koomanachai, P., C.B. Landersdorfer, G. Chen, H.J. Lee, A. Jitmuang, S. Wasuwattakul, . . .and V. Thamlikitkul. Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in End-Stage Renal Disease Patients Receiving Continuous Ambulatory Peritoneal Dialysis. Antimicrobial Agents and Chemotherapy 58(1): 440-446, 2014.
  30. Kosloski, M.P., D.S. Pisal, D.E. Mager and S.V. Balu-Iyer. Nonlinear pharmacokinetics of factor VIII and its phosphatidylinositol lipidic complex in hemophilia A mice. Biopharmaceutics & Drug Disposition 35(3): 154-163, 2014.
  31. Kosta, P.J. Validation of Individual Non-Linear Predictive Pharmacokinetic Parameters in a Rabbit Phenytoin Model. Tropical Journal of Pharmaceutical Research 13(8): 1295-1302, 2014.
  32. Livermore, J., S.J. Howard, A.D. Sharp, J. Goodwin, L. Gregson, T. Felton, . . .and W.W. Hope. Efficacy of an Abbreviated Induction Regimen of Amphotericin B Deoxycholate for Cryptococcal Meningoencephalitis: 3 Days of Therapy Is Equivalent to 14 Days. mBio 5(1): e00725-00713, 2014.
  33. Lodise, T.P., G.L. Drusano, E. Zasowski, A. Dihmess, V. Lazariu, L. Cosler and L.-A. McNutt. Vancomycin Exposure in Patients With Methicillin-Resistant Staphylococcus aureus Bloodstream Infections: How Much Is Enough? Clinical Infectious Diseases 59(5): 666-675, 2014.
  34. Louie, A., W. Liu, M. VanGuilder, M.N. Neely, A. Schumitzky, R. Jelliffe, . . .and G.L. Drusano. Combination Treatment With Meropenem Plus Levofloxacin Is Synergistic Against Pseudomonas aeruginosa Infection in a Murine Model of Pneumonia. Journal of Infectious Diseases 211(8): 1326-1333, 2014.
  35. Lu, D., J. Jin, S. Girish, P. Agarwal, D. Li, S. Prabhu, . . .and C. Ng. Semi-mechanistic Multiple-Analyte Pharmacokinetic Model for an Antibody-Drug-Conjugate in Cynomolgus Monkeys. Pharmaceutical Research 32(6): 1907-1919, 2014.
  36. MacVane, S.H., W. So, D.P. Nicolau and J.L. Kuti. In Vitro Activity of Human-Simulated Epithelial Lining Fluid Exposures of Ceftaroline, Ceftriaxone, and Vancomycin against Methicillin-Susceptible and -Resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 58(12): 7520-7526, 2014.
  37. Mahmood, I., C.-M. Staschen and K. Goteti. Prediction of Drug Clearance in Children: an Evaluation of the Predictive Performance of Several Models. The AAPS Journal 16(6): 1334-1343, 2014.
  38. McGinn, K., M. Reichert, E. Kincaid and D. Grosshans. 618: Inhaled Epoprostenol Vs Inhaled Nitric Oxide for Acute Pulmonary Hypertension After Cardiac Surgery. Critical Care Medicine 42(12): A1508-A1509, 2014.
  39. McPeake, J., A. O’Neill, E. Forrest, T. Quasim and J. Kinsella. 616: A Qualitatice Study Exploring The Impact of Alcohol Use Disorders On Recovery From ICU. Critical Care Medicine 42(12): A1508, 2014.
  40. Morris, M. and R. Dave. Pharmacokinetics and Pharmacodynamics of Phenethyl Isothiocyanate: Implications in Breast Cancer Prevention. The AAPS Journal 16(4): 705-713, 2014.
  41. Morse, B., N. Vijay and M. Morris. Mechanistic Modeling of Monocarboxylate Transporter-Mediated Toxicokinetic/Toxicodynamic Interactions Between γ-Hydroxybutyrate and l-Lactate. The AAPS Journal 16(4): 756-770, 2014.
  42. Neely, M.N., G. Youn, B. Jones, R.W. Jelliffe, G.L. Drusano, K.A. Rodvold and T.P. Lodise. Are Vancomycin Trough Concentrations Adequate for Optimal Dosing? Antimicrobial Agents and Chemotherapy 58(1): 309-316, 2014.
  43. Nguyen, T.T. and F. Mentre. Evaluation of the Fisher information matrix in nonlinear mixed effect models using adaptive Gaussian quadrature. Computational Statistics & Data Analysis 80: 57-69, 2014.
  44. Okusanya, O.O., S.M. Bhavnani, J.P. Hammel, A. Forrest, C.C. Bulik, P.G. Ambrose and R. Gupta. Evaluation of the Pharmacokinetic-Pharmacodynamics of Liposomal Amikacin for Inhalation in Cystic Fibrosis Patients with Chronic Pseudomonal Infections Using Data from Two Phase 2 Clinical Studies. Antimicrobial Agents and Chemotherapy 58(9): 5005-5015, 2014.
  45. Ottosson, W., J.A.L. Andersen, S. Borrisova, A. Mellemgaard and C.F. Behrens. Deformable image registration for geometrical evaluation of DIBH radiotherapy treatment of lung cancer patients. Journal of Physics: Conference Series 489(1): 012077, 2014.
  46. Pai, M.P., A. Russo, A. Novelli, M. Venditti and M. Falcone. Simplified Equations using two Concentrations to Calculate Area under the Curve for Antimicrobials with Concentration-Dependent Pharmacodynamics: Daptomycin as a motivating example. Antimicrobial Agents and Chemotherapy 58(6): 3162-3167, 2014.
  47. Patel, K., K.T. Batty, B.R. Moore, P.L. Gibbons and C.M. Kirkpatrick. Predicting the parasite killing effect of artemisinin combination therapy in a murine malaria model. Journal of Antimicrobial Chemotherapy 69(8): 2155-2163, 2014.
  48. Perera, V., R.R. Bies, G. Mo, M.J. Dolton, V.J. Carr, A.J. McLachlan, . . .and A. Forrest. Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice. British Journal of Clinical Pharmacology 78(4): 800-814, 2014.
  49. Phe, K., Y. Lee, P.M. McDaneld, N. Prasad, T. Yin, D.A. Figueroa, . . .and V.H. Tam. In Vitro Assessment and Multicenter Cohort Study of Comparative Nephrotoxicity Rates Associated with Colistimethate versus Polymyxin B Therapy. Antimicrobial Agents and Chemotherapy 58(5): 2740-2746, 2014.
  50. Ramos-Martín, V., S. Paulus, S. Siner, E. Scott, K. Padmore, P. Newland, . . .and W.W. Hope. Population Pharmacokinetics of Teicoplanin in Children. Antimicrobial Agents and Chemotherapy 58(11): 6920-6927, 2014.
  51. Roberts, J.A., A.A. Udy, J.B. Bulitta, J. Stuart, P. Jarrett, T. Starr, . . .and J. Lipman. Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration. Journal of Antimicrobial Chemotherapy 69(9): 2508-2516, 2014.
  52. Salle, S., L. Chevillard, P. Risede, F. Cottin, O. Roussel and P. Houze. P41: Comparison of respiratory toxicity induced by two paraoxons in rat – research of toxicokinetic/ toxicodynamic relation. Toxicologie Analytique et Clinique 26(2): S47-S48, 2014.
  53. Scherkenbach, L.A., L.D. Coles, E.E. Patterson, J.C. Cloyd, L.E. Krach and R.L. Kriel. Pharmacokinetics and pharmacodynamics of intravenous baclofen in dogs: a preliminary study. Journal of Pharmacy and Pharmacology 66(7): 935-942, 2014.
  54. Shah, D., L. King, X. Han, J.-A. Wentland, Y. Zhang, J. Lucas, . . .and M. Leal. A Priori Prediction of Tumor Payload Concentrations: Preclinical Case Study with an Auristatin-Based Anti-5T4 Antibody-Drug Conjugate. The AAPS Journal 16(3): 1-12, 2014.
  55. Shah, D.K. and J.P. Balthasar. PK/TD modeling for prediction of the effects of 8C2, an anti-topotecan mAb, on topotecan-induced toxicity in mice. International Journal of Pharmaceutics 465(1–2): 228-238, 2014.
  56. Smith, D.C., P.D. Eisenberg, G. Manikhas, R. Chugh, M.A. Gubens, R.J. Stagg, . . .and B. Sikic. A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors. Clinical Cancer Research 20(24): 6295-6303, 2014.
  57. Spadiut, O. and C. Herwig. Dynamics in bioprocess development for Pichia pastoris. Bioengineered 5(6): 401-404, 2014.
  58. Tae Hwan Kima, B.S.S., Kyu-Bong Kimc, Seung Woo Shina, Su Hyun Seoka, Min Kyu Kima, Eun Jung Kimd, Dojung Kimd, Min Gi Kima, Eun-Seok Parka, Ju-Young Kima & Sun Dong Yooa*. Percutaneous Absorption, Disposition, and Exposure Assessment of Homosalate, a UV Filtering Agent, in Rats. Journal of Toxicology and Environmental Health, Part A: Current Issues 77(4): 202-213, 2014.
  59. Tan, M.W., D.C. Lye, T.-M. Ng, M. Nikolaou and V.H. Tam. Mathematical Model To Quantify the Effects of Risk Factors on Carbapenem-Resistant Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy 58(9): 5239-5244, 2014.
  60. . Quantifying the effects of risk factors on carbapenem resistant Acinetobacter baumannii: a mathematical modeling analysis. Antimicrobial Agents and Chemotherapy 58(9): 5239-5244, 2014.
  61. Wang, K., D. D’Argenio, E. Acosta, A. Sheth, C. Delille, J. Lennox, . . .and I. Ofotokun. Integrated Population Pharmacokinetic/Viral Dynamic Modelling of Lopinavir/Ritonavir in HIV-1 Treatment-Naïve Patients. Clinical Pharmacokinetics 53(4): 361-371, 2014.
  62. Wang, X., K. Owzar, P. Gupta, R.A. Larson, F. Mulkey, A.A. Miller, . . .and O. Alliance for Clinical Trials in. Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance). British Journal of Clinical Pharmacology 78(5): 1005-1013, 2014.
  63. Weiss, M., P. Arendt and R. Hassna. Effect of disease states on α1-adrenoceptor binding and signal transduction parameters in isolated perfused heart: quantification by pharmacokinetic-pharmacodynamic modelling. Journal of Pharmacy and Pharmacology 66(5): 668-676, 2014.
  64. Weiss, M., W. Kriangkrai and S. Sungthongjeen. An empirical model for dissolution profile and its application to floating dosage forms. European Journal of Pharmaceutical Sciences 56(0): 87-91, 2014.
  65. WilliamsLawrence E., W.M., KenanovaVania E., OlafsenTove, and YazakiPaul J.. Cancer Biotherapy & Radiopharmaceuticals. Numerical Comparison of Iodine-Based and Indium-Based Antibody Biodistributions. Cancer Biotherapy & Radiopharmaceuticals 29(3): 91-98, 2014.
  66. Yu, Y., V. Logovinsky, E. Schuck, J. Kaplow, M.-k. Chang, T. Miyagawa, . . .and J. Ferry. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel γ-secretase modulator, E2212, in healthy human subjects. The Journal of Clinical Pharmacology 54(5): 528-536, 2014.
  67. Yun, H.-y., W. Kang, B.-y. Lee, S. Park, Y.-R. Yoon, J. Yeul Ma and K.-i. Kwon. Semi-Mechanistic Modelling and Simulation of Inhibition of Platelet Aggregation by Antiplatelet Agents. Basic & Clinical Pharmacology & Toxicology 115(4): 352-359, 2014.
  68. Zhang, Y., C.-P. Hsu, J.-F. Lu, M. Kuchimanchi, Y.-N. Sun, J. Ma, . . .and D. D’Argenio. FLT3 and CDK4/6 inhibitors: Signaling mechanisms and tumor burden in subcutaneous and orthotopic mouse models of acute myeloid leukemia. Journal of Pharmacokinetics and Pharmacodynamics 41(6): 675-691, 2014.
  69. Zhou, A., G. Pacini, B. Ahrén and D. D’Argenio. Glucagon clearance is regulated by nutritional state: evidence from experimental studies in mice. Diabetologia 57(4): 801-808, 2014.
  70. Zhou, J., Z. Sulaiman, R.M. Llorin, K.-H. Hee, L.S.-U. Lee, D.C. Lye, . . .and V.H. Tam. Pharmacokinetics of ertapenem in outpatients with complicated urinary tract infections. Journal of Antimicrobial Chemotherapy 69(9): 2517-2521, 2014.